Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy. Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma. CHANHASSEN, Minn., May 15, 2025 —...
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas “SDT’s ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented.”...
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold The...
Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas,...
FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM) OAKDALE,...
Alpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary,...
ALPHEUS MEDICAL CLOSES $16M IN SERIES A FINANCING FOR NOVEL GLIOMA BRAIN CANCER TREATMENT Funds to support first-in-human (FIH) clinical trial of the company’s proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas OAKDALE,...
